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Introduction: This study explores patient preferences for involve-
ment in lung cancer treatment decisions and the extent of concor-
dance between the views of patients and physicians on decisional
roles. The impact of demographic and psychosocial characteristics
on the decisional role of patients is also examined.
Methods: Patients with relapsed non-small cell lung cancer who
were candidates for a phase II trial of erlotinib monotherapy were
recruited. Patients were interviewed after they had learned of their
relapse and the treatment decision had been made but before phar-
macologic intervention.
Results: Most of the 28 participants were married, had a smoking
history, and were well educated. They reported moderate levels of
depression and anxiety. Initially, 14% of the patients reported a
preference for active decision making; later, 29% believed that the
primary responsibility for the treatment decision had been theirs.
Only 54% of the patients agreed with the physician’s assessment of
how the treatment decision was made (  0.31; test of symmetry,
p  0.23). The depression score was significantly associated with a
patient’s preferred level of control (p  0.01).
Conclusions: The limited concordance between patient preference
and perception and between patient and physician perceptions re-
garding how the treatment decision was made suggests that physi-
cians should more accurately identify patient preferences by directly
asking patients at the beginning of each clinical encounter.
Key Words: Decisional role, Non-small cell lung cancer, Percep-
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The past 2 decades have witnessed increased research inpatient preferences for information and decisional roles in
the treatment process, and a shift to a more patient-centered
approach to healthcare delivery. This movement, often
termed shared decision making, emphasizes a more active,
participatory role for patients and a more tailored approach to
patient education by healthcare providers.1–3
A growing body of literature demonstrates that decision
making shared between patients and providers can result in a
variety of benefits, including improved patient satisfaction
and clinical outcomes.4–11 Considerable attention has focused
on identifying patient preferences and the extent to which
these preferences are met in patient-provider interactions.
These issues have been extensively examined with breast
cancer patients12,13 but not fully with lung cancer patients.
We investigated the degree of desired involvement in
treatment decisions of a sample of lung cancer patients who
were enrolled in a phase II trial of erlotinib therapy, and we
explored the extent to which these patient preferences were
met. We also examined whether anxiety and depression play
a role in decision-making preferences.
METHODS
Patients
Between January and December 2008, Japanese pa-
tients with non-small cell lung cancer in six institutes affili-
ated with Okayama Lung Cancer Study Group who relapsed
to the first-line or second-line chemotherapy participated in a
prospective phase II trial of erlotinib monotherapy.14 The
phase II trial included the current study as a preplanned
subset analysis. Of the 30 patients, 28 consented to this subset
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analysis; the other 2 declined to participate. This study was
approved by the institutional review boards of all participat-
ing institutes.
Study Flow
The main outcome measures of this study were three
parallel versions of a control preferences scale (Table 1).15
All the study patients were interviewed on recruitment to the
study,14 which was after they had learned of their lung cancer
recurrence and the treatment decision had been made, just
before therapy began. Patients were interviewed using ques-
tionnaires that assessed sociodemographic characteristics,
psychosocial constructs, and decisional-role outcome mea-
sures (patient perceptions; Table 1). Sociodemographic vari-
ables included date of birth, marital status, and education.
Patients also completed the Hospital Anxiety and Depression
Scale (HADS),16 which screens psychiatric problems in med-
ically ill patients by using a 4-point, 14-item self-assessment
scale to measure 2 factors of psychologic distress: anxiety
and depression. Physicians attending the patients were also
interviewed to assess their perceptions.
Data Analysis
Differences among the groups were evaluated using
Fisher’s exact test and the Kruskal-Wallis equality-of-popu-
lations rank test. To determine where deviations occurred
between patient perceptions before and after the treatment
decision and between patients’ and physicians’ perceptions, 
statistics and a test for symmetry were applied to assess
agreement and discordance. For these analyses, the patient
preference scale was collapsed to three levels, similar to those
of previous studies (mostly patient, shared decision making,
and mostly physician; Table 1)17–19 because of the sparse
number of responses at the tails. Statistical analyses were
conducted using STATA version 10 software (College Sta-
tion, TX). Values of p  0.05 (two sided) were considered
statistically significant.
RESULTS
Patient Characteristics
Table 2 summarizes the patient characteristics. Most
were married males with a smoking history and high educa-
tion level. With regard to the clinical information, most had
adenocarcinoma and a history of platin use.
Patients posted relatively low baseline HADS scores
for both anxiety and depression. The median score was 6 for
each, with a range of 0 to 12 for anxiety and 0 to 16 for
depression. In general, women reported relatively high levels
of anxiety in communicating with their physician (median
scores: 8 for females versus 5 for males; p  0.03), whereas
the depression score was comparable between female and
male patients (median: 7.5 for females versus 6 for males;
p  0.35). The 28 patients were attended by a total of 17
physicians (15 male and 2 female), whose ages were in the
twenties to forties (median, thirties).
TABLE 1. Control Preferences Scale: Three Parallel Versions
Patient Preference Scale Patient Perception Scale Physician Perception Scale
I prefer to make the final selection about which
treatment I will receive.
I made the final decision about which treatment
I would receive.
The patient made the final decision about which
treatment she or he would receive.
I prefer to make the final selection of my
treatment after seriously considering my
doctor’s opinion.
I made the final selection of my treatment after
seriously considering my doctor’s opinion.
The patient made the final decision about which
treatment she or he would receive after
seriously considering my opinion.
I prefer that my doctor and I share
responsibility for deciding which treatment is
best for me.
My doctor and I shared responsibility for
deciding which treatment was best for me.
I shared responsibility with the patient for
making the final decision about treatment she
or he would receive.
I prefer that my doctor make the final decision
about which treatment will be used but
seriously consider my opinion.
My doctor made the final decision about which
treatment would be used but seriously
considered my opinion.
I made the final decision about which treatment
the patient would receive, after seriously
considering the patient’s opinion.
I prefer to leave all decisions regarding my
treatment to my doctor.
My doctor made all the decisions regarding my
treatment.
I made the final decision about which treatment
the patient would receive.
In this study, the scale was collapsed to three levels: mostly patient for the first and second options; shared decision making for the third; and mostly physician for the fourth
and fifth options of the patient preference, patient perception, and physician perception scales (see Methods).
TABLE 2. Clinical, Psychosocial, and Sociodemographic
Characteristics
No. of patients 28
Sociodemographic characteristics
Median age (range), yr 67 (35–88)
Gender (male/female) 22 (79%)/6 (21%)
Smoking history (yes/no) 20 (71%)/8 (29%)
Marital status (married/unmarried) 24 (86%)/4 (14%)
Education (posthigh-school graduate/
high-school graduate or less)
17 (61%)/5 (18%)a
Clinical characteristics
Tumor histology (adenocarcinoma/other) 19 (68%)/9 (32%)
Performance status (0/1–2) 6 (21%)/22 (79%)
Prior chemotherapy regimens (2/2) 12 (43%)/16 (57%)
Prior platin use (yes/no) 20 (71%)/8 (29%)
Respiratory comorbidity (yes/no) 5 (18%)/23 (82%)
Psychosocial characteristics, median (range)
HADS anxiety score 6 (0–12)
HADS depression score 6 (0–16)
a Data were not available for six patients.
HADS, Hospital Anxiety and Depression Scale.
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Decision Control Preferences
Seven (25%) of the patients favored a passive role in
treatment decision making, whereas 14% favored an active
role, and 61% preferred a collaborative role. Preference for
a passive role did not correlate with any of the clinical or
sociodemographic factors evaluated (Table 3). In contrast,
patient preferences were affected by their depression sta-
tus, with median depression scores of 7, 7, and 3 for the
active, shared, and passive roles, respectively (p  0.01;
Figure 1A). The groups also differed in anxiety status, with
median anxiety scores of 3, 7, and 3, respectively (p  0.01;
Figure 1B).
Patient Perceptions Versus Patient Preferences
and Physician Perceptions
Table 4 shows that 67.9% of the patients perceived that
they made the decision they had initially preferred, resulting
in between patient preferences and perceptions (  0.48;
test of symmetry, P  0.10). Table 5 contrasts the views of
patients and physicians with regard to the treatment decision.
Only 53.6% of patients agreed completely with those of their
physicians concerning who made the treatment decision (
0.31; test of symmetry, P  0.23), that is, compared with the
patients’ perceptions of their involvement in treatment deci-
sions, physicians tended to perceive that patients were more
actively involved. There was less discordance between the
patient preferences and physician perceptions with  of 0.23
(% agreement: 46.4%; Table 6).
DISCUSSION
Our results show that the perceptions of patients and
physicians with respect to their roles in treatment decisions
agreed in only half of the 28 cases. In addition, two thirds of
the 28 patients perceived that they made the decision in the
manner they had initially preferred. These results indicate
that concerns and management strategies were insufficiently
discussed between the patients and physicians.
One possible explanation for the discrepancy between
the views of patients and physicians regarding the patient
decisional role is that the physicians based their perceptions
on behavioral cues, which have been shown to be inconsistent
with patient perceptions.20,21 Physicians who want to meet
patient expectations may need to ask directly about role
preferences, instead of trying to discern them from opinions
offered or questions asked by the patient.12
We also used HADS to investigate depression and
anxiety status and the relationship between these states and
patient preferences. First, we observed relatively low overall
HADS depression and HADS anxiety scores, which were
almost identical to those of primary breast cancer patients.13
Generally, in contrast to breast cancer patients, patients with
relapsed non-small cell lung cancer have a poor prognosis,
with a median survival time of approximately 7 months.22
Thus, we initially thought that the 28 patients would report
higher HADS scores. Given that the general condition of
these patients was good enough for accrual into the clinical
trial, the HADS scores of these patients might have been
lower than what we had initially expected.
Second, we showed that HADS scores may affect
patient preferences. Although our data do not allow for causal
interpretation, patients with passive decision-making prefer-
ences had lower depression scores, compared with patients
with collaborative or active preferences. In contrast, in a
neoadjuvant setting for newly diagnosed breast cancer, pa-
tients with passive role preferences had higher HADS depres-
sion scores, perhaps because patients who are depressed
because of their symptoms prefer to leave their treatment
responsibility to the physician.13 Our findings are also in
contrast to two other studies that found no differences in
HADS scores among role preferences.12,23 These conflicting
results may be explained by differences in assessments,
samples, data analysis, or ethnicity.12,23 Further studies are
needed to determine the impact of depression and anxiety on
decision-making preferences.
TABLE 3. Patient Preferences Stratified by Clinical and
Sociodemographic Characteristics
Factor
Patient Preferences
pActive Shared Passive
Age (yr)
67a 2 (13) 9 (60) 4 (27) 0.99
67a 2 (15) 8 (62) 3 (23)
Gender
Male 3 (14) 13 (59) 6 (27) 0.99
Female 1 (17) 4 (67) 1 (17)
Smoking history
Yes 2 (10) 12 (60) 6 (30) 0.52
No 2 (25) 5 (63) 1 (13)
Marital status
Married 4 (17) 13 (54) 7 (29) 0.31
Unmarried 0 4 (100) 0
Tumor histology
Adenocarcinoma 3 (16) 13 (68) 3 (16) 0.26
Others 1 (11) 4 (44) 4 (44)
Performance status
0 0 5 (83) 1 (17) 0.54
1–2 4 (18) 12 (55) 6 (27)
No. of prior chemotherapy
regimens
2 1 (7) 9 (64) 4 (29) 0.75
2 3 (21) 8 (57) 3 (21)
Prior platin use
Yes 3 (15) 12 (60) 5 (25) 0.99
No 1 (13) 5 (63) 2 (25)
Respiratory comorbidity
Yes 0 5 (100) 0 0.28
No 4 (17) 12 (52) 7 (30)
Patient knowledge of epidermal
growth factor receptor-tyrosine
kinase inhibitors
Yes 3 (23) 7 (54) 3 (23) 0.49
No 1 (7) 10 (67) 4 (27)
Data are presented as N (%).
a Median age.
EGFR, epidermal growth factor receptor.
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We have several limitations. Because there were 17
physicians attended 28 patients meaning less than 2 patients
by physician, we could not sure that they provide the patients
with the same information. This may influence the principal
results. In addition, the sample size did not allow us to do
subgroup analyses. Furthermore, the control preferences scale
and the way physicians understood how patients took deci-
sions have not yet fully been validated extensively. Thus, our
results should be interpreted cautiously.
In conclusion, despite our small sample size, the HADS
score, and not the sociodemographic or clinical factors as-
sessed in this study, was associated with a preferred deci-
sional role. The overall lack of concordance between physi-
cian and patient perceptions of the decisional context
indicates a gap that must be narrowed. One reasonable and
unobtrusive approach would be for physicians to directly ask
about a patient’s preferences at the beginning of each clinical
encounter and to then check on the patient’s level of satis-
faction with the decision-making process.
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